A 10-month-old term boy, firstborn of a non-consanguinous relationship, presented with a history of prolonged crying and seizures. No significant antenatal history was given, and the child had attained normal milestones until the age of 5 months, after which his development deteriorated. On examination, the head size was 55 cm (more than the 97th percentile for age of the patient). There were no signs or symptoms of raised intracranial tension such as vomiting, papilloedema etc. There was no normal eye contact, and global spasticity was noted.
Excite 1.5T HD, USA). The MR study revealed bilaterally symmetrical confluent white matter hyperintensities on T2W images with frontal preponderance and involvement of the bilateral temporal and parietal lobes (Fig. 1) . The subcortical U fibres were involved. Symmetrical bilateral hyperintensities on T2W images were also seen in external capsule, internal capsule, fornix, extreme capsule, corpus callosum and head of caudate nucleus. White matter expansion with resultant widened gyri was noted in the affected regions. All these regions were hypo-intense on T1W and T2 FLAIR. A periventricular rim, T2 hyper, T1 hypointense, was seen along the lateral ventricles (Figs 2a  and 2b ). The frontal lobes showed symmetrical areas of cavitation in the periventricular region (Fig. 3) . Patchy symmetrical enhancement was noted in the periventricular rim and deep white matter of the frontal lobes (Figs 4a and 4b) . MR spectroscopy did not reveal raised N-acetylaspartate (NAA) or myoinositol peak. Based on these MR findings, a diagnosis of Alexander disease was made.
Discussion
Alexander disease (fibrinoid leucodystrophy), originally described by Alexander in 1949, 1 is a rare, fatal, nonfamilial leucoencephalopathy caused by astrocyte dysfunction characterised by missense mutation in the genes coding for glial fibrillary acidic protein(GFAP). 2 The disease is classified into 3 types:
Alexander disease (fibrinoid leucodystrophy; originally described by Alexander in 1949) is a rare, fatal, nonfamilial leucoencephalopathy caused by astrocyte dysfunction characterised by missense mutation in the genes coding for glial fibrillary acidic protein (GFAP). It typically presents with frontal preponderance of white matter abnormalities and macroencephaly. We report a case of leucoencephalopathy with macroencephaly that shows characteristic MRI features of Alexander disease. 
Fig. 2. T1W image (left) and T2W image (right) show a periventricular rim, hyperintense on T1W and hypointense on T2W, with cystic cavitation in the frontal periventricular region.
• cerebral Alexanders (type 1), which primarily has an infantile onset with the presence of seizures, psychomotor developmental retardation, macrocephaly and abnormalities in the superior frontal cerebral white matter observed in a brain MRI • bulbospinal Alexanders (type 2), which primarily has an adult onset with the presence of muscle weakness, hyperreflexia, bulbar or pseudobulbar symptoms, signal abnormalities and atrophy observed in an MRI of the medulla oblongata and upper cervical spinal cord • intermediate form (type 3) which has the characteristics of both the preceding. 3 The MR imaging patterns of Alexander disease have been described to be quite specific, dissimilar from patients observed in other white matter abnormalities either of known 4 or unknown origin. Five criteria were described by van der Knaap et al; 4 our patient met 4 of them, with the additional finding of rarely described periventricular cavitation/cysts. 6 Various differential diagnoses that were considered included Canavan disease, which is characterised by a combination of macroencephaly, extensive cerebral white matter changes (without frontal preponderance) and basal ganglia abnormalities. 5 However, contrast enhancement does not occur in Canavan disease, and the typical raised N-acetyl aspartate (NAA) peak on MR spectroscopy was absent in our patient. Traditionally, biopsy was necessary to diagnose the disease, but diagnosis can now be made by MR imaging, using the criteria defined by van der Knaap et al. 4 Additional confirmation can be obtained via genetic testing of a blood sample for missense mutation in the gene encoding for GFAP. 
